Develops buprenorphine-based prescription drugs for opioid dependence. Manufactures medications like Suboxone Film, Suboxone Tablet, and Subutex Tablet. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 20.5× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 64% of them.
Analysts' average target sits 39% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 12% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, INDV sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: INDV is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.